- Home
- HOTH vs EDSA Comparison
HOTH vs EDSA Comparison
Compare HOTH & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- EDSA
- Stock Information
- Founded
- HOTH 2017
- EDSA 2015
- Country
- HOTH United States
- EDSA Canada
- Employees
- HOTH N/A
- EDSA N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- EDSA Health Care
- Exchange
- HOTH Nasdaq
- EDSA Nasdaq
- Market Cap
- HOTH 5.8M
- EDSA 6.1M
- IPO Year
- HOTH 2019
- EDSA N/A
- Fundamental
- Price
- HOTH $0.81
- EDSA $1.91
- Analyst Decision
- HOTH Strong Buy
- EDSA Strong Buy
- Analyst Count
- HOTH 4
- EDSA 1
- Target Price
- HOTH $4.75
- EDSA $21.00
- AVG Volume (30 Days)
- HOTH 1.2M
- EDSA 31.2K
- Earning Date
- HOTH 12-24-2024
- EDSA 02-07-2025
- Dividend Yield
- HOTH N/A
- EDSA N/A
- EPS Growth
- HOTH N/A
- EDSA N/A
- EPS
- HOTH N/A
- EDSA N/A
- Revenue
- HOTH N/A
- EDSA N/A
- Revenue This Year
- HOTH N/A
- EDSA N/A
- Revenue Next Year
- HOTH N/A
- EDSA N/A
- P/E Ratio
- HOTH N/A
- EDSA N/A
- Revenue Growth
- HOTH N/A
- EDSA N/A
- 52 Week Low
- HOTH $0.58
- EDSA $1.69
- 52 Week High
- HOTH $1.73
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- HOTH 42.94
- EDSA 37.11
- Support Level
- HOTH $0.82
- EDSA $1.73
- Resistance Level
- HOTH $0.84
- EDSA $2.55
- Average True Range (ATR)
- HOTH 0.04
- EDSA 0.18
- MACD
- HOTH -0.00
- EDSA 0.03
- Stochastic Oscillator
- HOTH 14.50
- EDSA 25.58
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.